What Do We Know About Remdesivir Drug Interactions?

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐Co‐V‐2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a pro...

Full description

Saved in:
Bibliographic Details
Published inClinical and Translational Science Vol. 13; no. 5; pp. 842 - 844
Main Author Yang, Katherine
Format Journal Article Web Resource
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.09.2020
John Wiley and Sons Inc
Wiley
Subjects
Adenosine
Antiviral drugs
Bioavailability
Coronaviruses
COVID-19
DNA-directed RNA polymerase
Epithelial cells
Intracellular
Metabolites
Mortality
Multidrug resistance
Oral administration
Pandemics
Voriconazole
Online AccessGet full text

Cover

More Information
Summary:The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐Co‐V‐2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active metabolite (GS‐441524), and its triphosphate metabolite (GS‐443902) are needed.
ISSN:1752-8054
1752-8062
DOI:10.1111/cts.12815